Clinica Montecanal S.L. — Clinical Trial Site

13 Registered trials

6 Currently recruiting

Organisation

Clinica Montecanal S.L.

Location

Zaragoza, Spain

Identifier

ORG-100049257

Address

Calle Franz Schubert 2, 50012, Spain

Departments

#40616:Neuroscience Department
Departamento de Neurología
Neurologia
Neurology
Neuroscience
Psiquiatría

Clinical trials at this site (13)

Search interface

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting

2023-509807-34-00 Early Alzheimer’s Disease (Mild Cognitive Impairment an 4 2024-08-12
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 Psychosis associated with Alzheimer’s Disease 4 2025-07-11
A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease Recruiting

2024-516363-92-00 Psychosis Associated with Alzheimer’s Disease 5 2025-04-08
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended

2024-514680-26-00 Agitation Associated with Alzheimer’s Dementia 4 2025-07-17
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended

2023-507132-21-00 Early Parkinson's disease 10 2021-05-11
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404… Halted

2023-505096-68-00 Preclinical Alzheimer’s Disease 4 2025-01-14
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease Ended

2023-506872-29-00 Alzheimer's Disease 4 2023-04-13
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 Alzheimer’s Disease 4 2021-10-18
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504991-31-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-05-06